A Phase 4 interventional study of LCZ 696 and Placebo in Heart Failure, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Yale University · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Heart Failure by Yale University — 9 open to participants now, 12 under way, none of them phase 3. Heart Failure · Yale University.
Among the 33 studies in Heart Failure by Yale University, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2021, is one of 2 in phase 4, and was the 19th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →9 of the 33 studies in Heart Failure by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–85 · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 72 across the 27 interventional studies, 58 across the 6 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
4 of the studies in Heart Failure by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05323487Yale UniversityMechanisms of Diuretic Resistance in Heart Failure, Aim 1 | 2027-05-01 |
| NCT07398950Yale UniversityProspective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 2027-06 |
| NCT07281014Yale UniversityUnmitigated Aldosterone Signaling During Standard Clinical MRA Dosing | 2027-08 |
| NCT06933875Yale UniversityPromoting Palliative Care for People With Heart Failure | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Heart Failure by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality compared to enalapril in patients with heart failure (HF), reduced ejection fraction (EF), and increased brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) in the PARADIGM-HF trial. The PIONEER-HF study demonstrated the efficacy of LCZ696 in preventing rehospitalization in patients with acutely decompensated HF.
LCZ696 has been underutilized in heart failure, in part due to concerns about hypotension. NEP degrades several vasodilator peptides including bradykinin, substance P and brain-type natriuretic peptide. Decreased degradation of endogenous substance P could contribute to hypotension at initiation of LCZ696 through vasodilation or through increased natriuresis and diuresis. Antagonism of the NK1 receptor using aprepitant would be expected to prevent this effect.
Objectives
The main objectives of this mechanistic randomized, double-blind, crossover-design study are:
The primary objective is to test the hypothesis that endogenous substance P contributes to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis at initiation.
The secondary objective is to test the hypothesis that endogenous substance P contributes to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis after up-titration.
Eighty (80) subjects with stable heart failure who meet all inclusion/exclusion criteria will be enrolled. Subjects who qualify will collect their urine for 24 hours before each study day for measurement of volume, sodium and potassium. At the start of the study, they will stop their regular angiotensin-converting enzyme (ACE) inhibitor or ARB. After a 48-hour washout, they will undergo a study day in which they are given a single dose of 50 mg LCZ696. They will also receive either the NK1 receptor antagonist aprepitant or placebo vehicle in random order (double-blind). After a 96-hour washout, they will repeat the study day and receive a single dose of 50 mg LCZ696 and the opposite study drug (aprepitant or placebo). After completion of the two acute study days, subjects will take LCZ696 50 mg bid for two weeks, followed by LCZ696 100 mg bid for three weeks, and then LCZ696 200 mg bid, following the conservative up-titration protocol from the TITRATION study. Criteria for continuing up-titration appears in the full study protocol. On the 7th and 10th day of the 200 mg bid or highest tolerated dose, subjects will again undergo two more study days three days apart in which they are randomized to receive either aprepitant or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stable patients with a reduced (EF)
For female subjects, the following conditions must be met:
Exclusion Criteria:
Impaired renal function ( of \<30mL/min/1.73 m2) as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years:
a. eGFR (mL/min/1.73 m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant 120 mg. All participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant 120 mg, respectively.
Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant
After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant 120 mg. Participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant 120 mg and placebo, respectively.
Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant
After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and aprepitant 120 mg. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant 120 mg, respectively.
Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant
After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and aprepitant 120 mg. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant 120 mg and placebo, respectively.
Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant
Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
Also known as: Entresto
Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
Max Change in Mean Arterial Pressure (MAP)
Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days
Time frame: The maximal change in MAP, as measured by the lowest MAP recorded six hours following drug administration minus the baseline MAP.
Urine Sodium Excretion
Urine sodium excretion will be measured for six hours following administration of LCZ696 on each of the four study days.
Time frame: Total urine output from drug administration to six hours following drug administration
Heart Rate
Heart rate (HR) will be measured before and after LCZ696 on each of the four study days
Time frame: The maximum change in heart rate as measured by the highest heart rate recorded over six hours after drug administration minus the baseline heart rate.
Urine Volume
Urine volume will be measured for six hours following LCZ696 on each of the four study days.
Time frame: Over six hours on each of four study days
Renal Plasma Flow
Renal plasma flow (RPF) will be calculated from para-aminohippurate clearance prior to and following LCZ696 and normalized per body surface area.
Time frame: The change in renal plasma flow as measured by the renal plasma flow six hours following administration of the drug minus baseline renal plasma flow.
Glomerular Filtration Rate
Glomerular filtration rate (GFR) will be calculated from the clearance of iohexol prior to and following LCZ66 on each of the four study days and expressed as mL of blood cleared of creatinine per minute.
Time frame: The glomerular rate or iohexol clearance calculated based on iohexol concentrations measured serially for six hours after drug administration.
| Milestone | Placebo, Aprepitant, Placebo, Aprepitant | Placebo, Aprepitant, Aprepitant, Placebo | Aprepitant, Placebo, Placebo, Aprepitant | Aprepitant, Placebo, Aprepitant, Placebo |
|---|---|---|---|---|
| Started | 11 | 12 | 12 | 11 |
| Finished study day 1 | 8 | 11 | 12 | 10 |
| Finished study day 2 | 8 | 11 | 11 | 10 |
| Completed uptitration of sacubitril/valsartan | 4 | 10 | 9 | 6 |
| Finished study day 3 | 4 | 10 | 8 | 6 |
| Completed | 4 | 10 | 8 | 5 |
| Not completed | 7 | 2 | 4 | 6 |
Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days
| change in mmHg | Placebo | Aprepitant |
|---|---|---|
| Max Change in Mean Arterial Pressure (MAP) | -14.85 ± 10.23 | -12.37 ± 7.55 |
Urine sodium excretion will be measured for six hours following administration of LCZ696 on each of the four study days.
| mmol | Placebo | Aprepitant |
|---|---|---|
| Urine Sodium Excretion | 122.7 ± 56.3 | 136.8 ± 74.1 |
Heart rate (HR) will be measured before and after LCZ696 on each of the four study days
| change in bpm | Placebo | Aprepitant |
|---|---|---|
| Heart Rate | 12.81 ± 7.72 | 15.30 ± 9.30 |
Urine volume will be measured for six hours following LCZ696 on each of the four study days.
| mL | Placebo | Aprepitant |
|---|---|---|
| Urine Volume | 649.8 ± 337.0 | 641.7 ± 300.0 |
Renal plasma flow (RPF) will be calculated from para-aminohippurate clearance prior to and following LCZ696 and normalized per body surface area.
| change in mL/min/1.73m2 | Placebo | Aprepitant |
|---|---|---|
| Renal Plasma Flow | 1.82 ± 111.9 | 16.7 ± 80.3 |
Glomerular filtration rate (GFR) will be calculated from the clearance of iohexol prior to and following LCZ66 on each of the four study days and expressed as mL of blood cleared of creatinine per minute.
| mL/min | Placebo | Aprepitant |
|---|---|---|
| Glomerular Filtration Rate | 83.1 ± 36.8 | 70.6 ± 29.5 |
Collected over Seven to eight weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior to First Study Day | 0/46 (0%) | 1/46 (2.2%) | 0/46 (0%) |
| Acute Study Day Placebo | 0/40 (0%) | 0/40 (0%) | 2/40 (5%) |
| Acute Study Day Aprepitant | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| LCZ699 (Entresto) Uptitration Period 50 mg Bid | 0/37 (0%) | 1/37 (2.7%) | 2/37 (5.4%) |
| LCZ699 (Entresto) Uptitration Period 100 mg Bid | 0/32 (0%) | 1/32 (3.1%) | 1/32 (3.1%) |
| LCZ699 (Entresto) Uptitration Period 200 mg Bid | 0/29 (0%) | 0/29 (0%) | 1/29 (3.4%) |
| Chronic Study Plus Placebo | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| Chronic Study Day Plus Aprepitant | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| Event | Prior to First Study Day | Acute Study Day Placebo | Acute Study Day Aprepitant | LCZ699 (Entresto) Uptitration Period 50 mg Bid | LCZ699 (Entresto) Uptitration Period 100 mg Bid | LCZ699 (Entresto) Uptitration Period 200 mg Bid | Chronic Study Plus Placebo | Chronic Study Day Plus Aprepitant |
|---|---|---|---|---|---|---|---|---|
| fluid overlaodCardiac disorders | 0/46 | 0/40 | 0/41 | 0/37 | 1/32 | 0/29 | 0/28 | 0/27 |
| SyncopeCardiac disorders | 0/46 | 0/40 | 0/41 | 1/37 | 0/32 | 0/29 | 0/28 | 0/27 |
| abscessInfections and infestations | 1/46 | 0/40 | 0/41 | 0/37 | 0/32 | 0/29 | 0/28 | 0/27 |
| Event | Prior to First Study Day | Acute Study Day Placebo | Acute Study Day Aprepitant | LCZ699 (Entresto) Uptitration Period 50 mg Bid | LCZ699 (Entresto) Uptitration Period 100 mg Bid | LCZ699 (Entresto) Uptitration Period 200 mg Bid | Chronic Study Plus Placebo | Chronic Study Day Plus Aprepitant |
|---|---|---|---|---|---|---|---|---|
| hypotensionVascular disorders | 0/46 | 0/40 | 1/41 | 2/37 | 0/32 | 0/29 | 1/28 | 1/27 |
| intravenous catheter infiltrationInvestigations | 0/46 | 2/40 | 0/41 | 0/37 | 0/32 | 0/29 | 0/28 | 1/27 |
| atrial fibrillationCardiac disorders | 0/46 | 0/40 | 0/41 | 0/37 | 1/32 | 1/29 | 0/28 | 0/27 |
participants who completed four study days
| Age, Continuous(years) | Placebo, Aprepitant, Placebo, Aprepitant | Placebo, Aprepitant, Aprepitant, Placebo | Aprepitant, Placebo, Placebo, Aprepitant | Aprepitant, Placebo, Aprepitant, Placebo | Total |
|---|---|---|---|---|---|
| Mean | 61.97 ± 3.22 | 51.32 ± 14.55 | 56.72 ± 13.87 | 59.12 ± 18.34 | 57.25 ± 14.09 |
| Sex: Female, Male(Participants) | Placebo, Aprepitant, Placebo, Aprepitant | Placebo, Aprepitant, Aprepitant, Placebo | Aprepitant, Placebo, Placebo, Aprepitant | Aprepitant, Placebo, Aprepitant, Placebo | Total |
|---|---|---|---|---|---|
| Female | 2 | 1 | 3 | 2 | 8 |
| Male | 2 | 9 | 5 | 4 | 20 |
| Race (NIH/OMB)(Participants) | Placebo, Aprepitant, Placebo, Aprepitant | Placebo, Aprepitant, Aprepitant, Placebo | Aprepitant, Placebo, Placebo, Aprepitant | Aprepitant, Placebo, Aprepitant, Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 3 | 3 | 11 |
| White | 2 | 5 | 5 | 3 | 15 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ejection fraction(percent) | Placebo, Aprepitant, Placebo, Aprepitant | Placebo, Aprepitant, Aprepitant, Placebo | Aprepitant, Placebo, Placebo, Aprepitant | Aprepitant, Placebo, Aprepitant, Placebo | Total |
|---|---|---|---|---|---|
| Median | 35.00 ± 12.24 | 37.50 ± 10.77 | 38.75 ± 12.27 | 38.00 ± 10.70 | 37.50 ± 10.54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in May 2025, 47 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's 47 months is above that.
Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.